Fecal Carriage of Multidrug-Resistant Organisms Increases the Risk of Hepatic Encephalopathy in Cirrhotic Patients: Insights from Gut Microbiota and Metabolite Features

Overview

Journal Res Sq

Date 2024 May 20

PMID 38766152

Authors

Peishan Wu

Pei-Chang Lee

Tien-En Chang

Yun-Cheng Hsieh

Jen-Jie Chiou

Chao-Hsiung Lin

Yi-Long Huang

Yi-Tsung Lin

Teh-Ia Huo

Bernd Schnabl

Kuei-Chuan Lee

Ming-Chih Hou

Affiliations

Soon will be listed here.

Abstract

Background: Impact of fecal colonization by multidrug-resistant organisms (MDROs) on changes in gut microbiota and associated metabolites, as well as its role in cirrhosis-associated outcomes, has not been thoroughly investigated.

Methods: Eighty-eight cirrhotic patients and 22 healthy volunteers were prospectively enrolled with analysis conducted on plasma metabolites, fecal MDROs, and microbiota. Patients were followed for a minimum of one year. Predictive factors for cirrhosis-associated outcomes were identified using Cox proportional hazards regression models, and risk factors for fecal MDRO carriage were assessed using logistic regression model. Correlations between microbiota and metabolic profiles were evaluated through Spearman's rank test.

Results: Twenty-nine (33%) cirrhotic patients exhibited MDRO carriage, with a notably higher rate of hepatic encephalopathy (HE) in MDRO carriers (20.7% vs. 3.2%, = 0.008). Cox regression analysis identified higher serum lipopolysaccharide levels and fecal MDRO carriage as predictors for HE development. Logistic regression analysis showed that MDRO carriage is an independent risk factor for developing HE. Microbiota analysis showed a significant dissimilarity of fecal microbiota between cirrhotic patients with and without MDRO carriage ( = 0.033). Thirty-two metabolites exhibiting significantly different expression levels among healthy controls, cirrhotic patients with and without MDRO carriage were identified. Six of the metabolites showed correlation with specific bacterial taxa expression in MDRO carriers, with isoaustin showing significantly higher levels in MDRO carriers experiencing HE compared to those who did not.

Conclusion: Fecal MDRO carriage is associated with altered gut microbiota, metabolite modulation, and an elevated risk of HE occurrence within a year.

References

Bajaj J, Hylemon P, Ridlon J, Heuman D, Daita K, White M . Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2012; 303(6):G675-85. PMC: 3468538. DOI: 10.1152/ajpgi.00152.2012. View

Fernandez J, Piano S, Bartoletti M, Wey E . Management of bacterial and fungal infections in cirrhosis: The MDRO challenge. J Hepatol. 2021; 75 Suppl 1:S101-S117. DOI: 10.1016/j.jhep.2020.11.010. View

Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L . Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014; 513(7516):59-64. DOI: 10.1038/nature13568. View

Bajaj J, Tandon P, OLeary J, Reddy K, Garcia-Tsao G, Thuluvath P . Admission Serum Metabolites and Thyroxine Predict Advanced Hepatic Encephalopathy in a Multicenter Inpatient Cirrhosis Cohort. Clin Gastroenterol Hepatol. 2022; 21(4):1031-1040.e3. PMC: 11000256. DOI: 10.1016/j.cgh.2022.03.046. View

Rubio Garcia E, Vergara A, Aziz F, Narvaez S, Cuesta G, Hernandez M . Changes in the gut microbiota and risk of colonization by multidrug-resistant bacteria, infection, and death in critical care patients. Clin Microbiol Infect. 2022; 28(7):975-982. DOI: 10.1016/j.cmi.2022.01.004. View

Zhang Z, Zhai H, Geng J, Yu R, Ren H, Fan H . Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing. Am J Gastroenterol. 2013; 108(10):1601-11. DOI: 10.1038/ajg.2013.221. View

Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen K . Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014; 60(2):715-35. DOI: 10.1002/hep.27210. View

Panwar R, Sequeira R, Clarke T . Microbiota-mediated protection against antibiotic-resistant pathogens. Genes Immun. 2021; 22(5-6):255-267. PMC: 8497270. DOI: 10.1038/s41435-021-00129-5. View

Araos R, Tai A, Snyder G, Blaser M, DAgata E . Predominance of Lactobacillus spp. Among Patients Who Do Not Acquire Multidrug-Resistant Organisms. Clin Infect Dis. 2016; 63(7):937-943. PMC: 5019285. DOI: 10.1093/cid/ciw426. View

10.

Carlet J, Pulcini C, Piddock L . Antibiotic resistance: a geopolitical issue. Clin Microbiol Infect. 2014; 20(10):949-53. DOI: 10.1111/1469-0691.12767. View

11.

Gupta T, Lochan D, Verma N, Rathi S, Agrawal S, Duseja A . Prediction of 28-day mortality in acute decompensation of cirrhosis through the presence of multidrug-resistant infections at admission. J Gastroenterol Hepatol. 2019; 35(3):461-466. DOI: 10.1111/jgh.14788. View

12.

Ferstl P, Filmann N, Heilgenthal E, Schnitzbauer A, Bechstein W, Kempf V . Colonization with multidrug-resistant organisms is associated with in increased mortality in liver transplant candidates. PLoS One. 2021; 16(1):e0245091. PMC: 7822319. DOI: 10.1371/journal.pone.0245091. View

13.

Chen Z, Ruan J, Li D, Wang M, Han Z, Qiu W . The Role of Intestinal Bacteria and Gut-Brain Axis in Hepatic Encephalopathy. Front Cell Infect Microbiol. 2021; 10:595759. PMC: 7859631. DOI: 10.3389/fcimb.2020.595759. View

14.

Buffie C, Pamer E . Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol. 2013; 13(11):790-801. PMC: 4194195. DOI: 10.1038/nri3535. View

15.

Ji J, Wu S, Sheng L, Sun J, Ye Y, Zhang Y . Metabolic reprogramming of the glutathione biosynthesis modulates the resistance of Derby to ceftriaxone. iScience. 2023; 26(8):107263. PMC: 10432962. DOI: 10.1016/j.isci.2023.107263. View

16.

Aira A, Feher C, Rubio E, Soriano A . The Intestinal Microbiota as a Reservoir and a Therapeutic Target to Fight Multi-Drug-Resistant Bacteria: A Narrative Review of the Literature. Infect Dis Ther. 2019; 8(4):469-482. PMC: 6856238. DOI: 10.1007/s40121-019-00272-7. View

17.

Schuppan D, Afdhal N . Liver cirrhosis. Lancet. 2008; 371(9615):838-51. PMC: 2271178. DOI: 10.1016/S0140-6736(08)60383-9. View

18.

Seo Y, Shah V . The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol. 2013; 18(4):337-46. PMC: 3540369. DOI: 10.3350/cmh.2012.18.4.337. View

19.

Kim M, Cardoso F, Pawlowski A, Wunderink R, Ladner D, Abraldes J . The impact of multidrug-resistant microorganisms on critically ill patients with cirrhosis in the intensive care unit: a cohort study. Hepatol Commun. 2023; 7(2):e0038. PMC: 10019237. DOI: 10.1097/HC9.0000000000000038. View

20.

Bajaj J, Ridlon J, Hylemon P, Thacker L, Heuman D, Smith S . Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2011; 302(1):G168-75. PMC: 3345956. DOI: 10.1152/ajpgi.00190.2011. View